Urticarial Vasculitis Diagnosis and Management

Diagnostic Approach

Urticarial vasculitis presents with urticarial lesions that last longer than 24 hours, a key diagnostic feature, according to the British Journal of Dermatology 1
The condition should be distinguished from chronic spontaneous urticaria, where lesions typically last 2-24 hours, as noted by the British Journal of Dermatology 1, 2
Lesional skin biopsy is essential to confirm small-vessel vasculitis, with key histological features including leucocytoclasia, endothelial cell damage, perivascular fibrin deposition, and red cell extravasation, as stated by the British Journal of Dermatology 1
A full vasculitis screen, including serum complement assays, is necessary to distinguish normocomplementemic from hypocomplementemic disease, according to the British Journal of Dermatology 1

Second-generation H1-antihistamines at standard doses are recommended as first-line therapy for mild cases, as suggested by the British Journal of Dermatology 3
The British Journal of Dermatology recommends increasing antihistamine dose above manufacturer's recommendation if response is inadequate, and considering offering at least two different nonsedating H1 antihistamines as responses vary between individuals 3
For moderate disease, increasing antihistamine dose and considering adding H2-antihistamines or antileukotrienes for resistant cases is advised, according to the British Journal of Dermatology 3, 4
Systemic corticosteroids for short courses in severe cases, and more prolonged treatment may be necessary for urticarial vasculitis, as noted by the British Journal of Dermatology 4

Minimizing nonspecific aggravating factors, such as overheating, stress, and alcohol, is recommended, as stated by the British Journal of Dermatology 1
Avoiding drugs that can worsen urticaria, such as aspirin, NSAIDs, and codeine, is advised, according to the British Journal of Dermatology 1
Cooling antipruritic lotions, such as calamine or 1% menthol in aqueous cream, can provide symptomatic relief, as suggested by the British Journal of Dermatology 1
Patient education about the chronic nature of the condition and potential for eventual recovery is important, as noted by the British Journal of Dermatology 1

Regular assessment of disease activity, impact on quality of life, and treatment response is necessary, as recommended by the Journal of Allergy and Clinical Immunology 5
Monitoring complement levels in hypocomplementemic UV is crucial, according to the British Journal of Dermatology 1

The British Journal of Dermatology recommends distinguishing urticarial vasculitis from chronic urticaria based on lesion duration, with urticarial vasculitis lesions lasting >24 hours 6
For mild disease, the Journal of Allergy and Clinical Immunology suggests increasing antihistamine dose up to 4x the standard dose if inadequate control is achieved after 2-4 weeks 7, 8
The Journal of Allergy and Clinical Immunology recommends considering adding H2-antihistamines or antileukotrienes for resistant cases 6

For moderate disease, the Journal of Allergy and Clinical Immunology suggests starting with high-dose second-generation H1-antihistamines (up to 4x standard dose) and adding short courses of systemic corticosteroids if necessary 7, 8, 9
The Journal of Allergy and Clinical Immunology recommends adding omalizumab 300mg every 4 weeks if inadequate response is achieved with antihistamines and corticosteroids 8
For severe disease, the British Journal of Dermatology suggests using systemic corticosteroids as initial therapy (prednisolone 0.5-1mg/kg/day) and adding immunomodulatory agents to allow steroid tapering 9
The Journal of Allergy and Clinical Immunology recommends considering cyclosporine (up to 5mg/kg body weight) as an immunomodulatory agent for severe disease 8, 10

The Journal of Allergy and Clinical Immunology suggests regular assessment of disease activity using validated tools 11
For patients on cyclosporine, the Journal of Allergy and Clinical Immunology recommends monitoring blood pressure and renal function every 6 weeks 10
The Journal of Allergy and Clinical Immunology suggests stepping down therapy after achieving complete control for at least 3 consecutive months 7, 8

The American Academy of Allergy, Asthma, and Immunology recommends adding omalizumab 300mg every 4 weeks for inadequate response to high-dose antihistamines, with up to 6 months allowed for patients to respond 12
For insufficient response to standard omalizumab dosing, consider updosing by shortening the interval and/or increasing the dosage, with a maximum recommended dose of 600 mg every 14 days 12
Cyclosporine can be added for patients who do not respond to higher than standard doses of omalizumab, at a dose of up to 5mg/kg body weight, with monitoring of blood pressure and renal function every 6 weeks 12

The British Association of Dermatologists suggests that short tapering courses of oral steroids over 3–4 weeks may be necessary for urticarial vasculitis, and long-term oral corticosteroids should not be used except in very selected cases under regular specialist supervision 13

Regular assessment of disease activity, impact on quality of life, and treatment response is recommended at every visit, using validated patient-reported outcome measures (PROMs) to monitor disease activity 14